FairValu
BETA
PFIZER INC

PFIZER INC

PFE

Drug Manufacturers - General • Healthcare

Current Price
$25.900.00%
Market Cap
$147.62B
Volume
-
Avg Vol (3M): -
Next Earnings
-
52 Week Range
Low: $--High: $--

Comprehensive AI Analysis

AI Analysis of PFE's Strategic Position

Access detailed SWOT, moat analysis, growth sustainability, and risk assessment powered by Vertex AI.

Summary

Multi-agent institutional research for PFE

Factor Scorecard

Factor scores will populate once the financial statement data finishes loading.

Price Chart

PFE via TradingView

Loading TradingView chart...

Overview

Quarterly income statement data isn't available from current approved sources.

No Data

No annual financial data available.

Analyst Consensus

0 Analysts
Recommendation mix unavailable from the current feed
Buy
-
Hold
-
Sell
-

Coverage count comes from 0 analyst opinions, but the Buy/Hold/Sell mix was not included in the current payload.

Price Target

N/AAverage Target
Low
N/A
Current
$25.90
High
N/A

Peer Comparison

TickerPrice
PFEPFIZER INC
$25.90
Financial data not available for quantitative analysis.
Company News & Profile

Loading latest news...

About the Company

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Next Earnings Date

Jul 29, 2026